| Nomenclature | FPR2/ALX | OXE receptor |
| HGNC, UniProt | FPR2, P25090 | OXER1, Q8TDS5 |
| Principal transduction | Gi 1078 | Gi/o 1070,1071,1074,1083 |
| Rank order of potency | LXA4=aspirin triggered lipoxin A4=ATLa2>LTC4=LTD4>>15-deoxy-LXA4>>fMet-Leu-Phe 1060,1061,1063,1065,1098 | 5-oxo-ETE, 5-oxo-C20:3, 5-oxo-ODE > 5-oxo-15-HETE > 5S-HPETE > 5S-HETE 1070,1074,1086 |
| Endogenous agonists (pKi) | aspirin triggered lipoxin A4 (Selective), LXA4 (Selective) (pEC50 ∼12.0) 1075, resolvin D1 (Selective) (pEC50 ∼11.9) 1075 | 5-oxo-ETE (Selective) (pEC50 8.3–8.5) 1064,1084,1086,1089,1094 |
| Selective antagonists (pKi) | ATLa2 1066 | – |
| Radioligands (Kd) | [3H]LXA4 (Agonist, Full agonist) (5×10−10 – 7×10−10 M) 1061,1062 | [3H]5-oxo-ETE (Agonist) (3.8×10−9 M) 1084 |
| Comment | The agonist activity of the lipid mediators described has been questioned 1067,1088, which may derive from batch-to-batch differences, partial agonism or biased agonism. | – |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.